Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
Invivyd, Inc.
IVVD · SEC Filings
website
122
Invivyd, Inc., a biopharmaceutical firm in its clinical development phase, operates within the Unite...
Price
0.5962
Market Cap
176.86 M
Float
267.46 M
Country
US
Sector
Healthcare
Exchange
NASDAQ
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about IVVD
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
Invivyd, Inc.
IVVD · SEC Filings
267.46 M
Float
0.5962
Price
176.86 M
Market Cap
Financials
TYPE
HEADLINE
FILED AT
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 13, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 14, 2026
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 5, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 6, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 14, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 15, 2025
News
TYPE
HEADLINE
FILED AT
8-K
Invivyd Announces Positive Topline LIBERTY Phase 3 Study Results for VYD2311 and Outlines BLA Submission Plans
Sep 29, 2026
8-K
Invivyd Appoints Marc W. Elia as CEO and Provides Update on VYD2311 Clinical Programs
Sep 1, 2026
8-K
Invivyd Reports Second Quarter 2026 Financial Results and Business Updates
Aug 13, 2026
8-K
Invivyd, Inc. Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price
Jul 24, 2026
8-K
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA®
Jul 6, 2026
8-K
Invivyd, Inc. Announces Results of 2026 Annual Meeting of Stockholders
May 19, 2026
Prospectus
TYPE
HEADLINE
FILED AT
424B5
REGISTERED OFFERING
Nov 18, 2025
424B5
PENDING FIXED PRICE OFFERING | Bank: Cantor
Nov 17, 2025
424B5
REGISTERED OFFERING
Aug 22, 2025
424B5
PENDING FIXED PRICE OFFERING | Bank: Cantor
Aug 20, 2025
424B5
ATM | Offering amount: $75,000,000
Dec 22, 2023
424B4
OFFERING | Shares amount: 18,200,000 | Share price: $17.00 | Offering amount: $309,400,000.00
Aug 6, 2021
Registrations
TYPE
HEADLINE
FILED AT
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
May 14, 2026
S-3/A
SHARE RESALE REGISTRATION
Dec 19, 2025
FWP
Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
Nov 17, 2025
S-3
October 2025 SHELF | Offering amount: $350,000,000
Oct 2, 2025
FWP
Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
Aug 20, 2025
S-8
Registration
May 9, 2024
Proxies
TYPE
HEADLINE
FILED AT
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 6, 2026
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 6, 2026
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 7, 2025
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 7, 2025
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 18, 2024
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 10, 2023
Ownerships
TYPE
HEADLINE
FILED AT
4
Sheffield Ian (Reporting)
Sep 2, 2026
3
Sheffield Ian (Reporting)
Sep 2, 2026
4
Elia Marc (Reporting)
Sep 1, 2026
4
Lee Timothy Edward (Reporting)
Aug 18, 2026
4
Green Julie (Reporting)
Aug 18, 2026
4
Duke William E. (Reporting)
Aug 18, 2026
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
EFFECT
Form EFFECT - Notice of Effectiveness
Dec 29, 2025
CORRESP
Form CORRESP - Correspondence
Dec 19, 2025
EFFECT
Form EFFECT - Notice of Effectiveness
Apr 22, 2024
CORRESP
Form CORRESP - Correspondence
Apr 18, 2024
LETTER
Form UPLOAD - SEC-generated letter
Feb 23, 2024
EFFECT
Form EFFECT - Notice of Effectiveness
Oct 6, 2022
